biogen share rebound strongli updat phase
alzheim data earn
share biogen inc open nearli higher today firm
announc plan submit biolog licens applic fda
earli alzheim drug aducanumab base new analysi
larger dataset two phase studi compani also announc
prior market open morn biogen inc eisai co
ltd announc consult food drug
administr fda plan pursu regulatori approv aducanumab
investig treatment earli alzheim diseas
compani outlin report decis file base new
analysi conduct consult fda larger dataset
phase clinic studi discontinu march follow
futil analysi compani note plan file biolog licens
applic bla earli submiss includ data
phase phase emerg engag studi
compani explain report aducanumab
investig human monoclon antibodi studi treatment earli
alzheim diseas licens aducanumab neurimmun
collabor develop licens agreement sinc octob
eisai collabor develop commerci
ceo michel vounatso comment devast diseas
affect ten million world-wide today announc truli hearten
fight alzheim result groundbreak research
testament steadfast determin follow scienc right
thing patient hope prospect offer patient first
therapi reduc clinic declin alzheim diseas potenti
implic result similar approach target amyloid beta
joint statement dr anton porsteinsson william sheila konar professor
psychiatri neurolog neurosci director univers rochest
alzheim diseas research educ program ad-car
princip investig ad larg dataset repres first time phase
studi demonstr clearanc aggreg amyloid beta reduc
clinic declin alzheim diseas provid new hope medic
commun patient famili tremend unmet medic
need alzheim diseas commun wait moment
commend fda medic commun patient
studi partner persist work make today announc
busi day firm also announc posit earn
separ releas today report compani indic revenu
increas billion compar billion
period dilut ep increas non-
dilut ep increas
ceo michel vounatso comment earn deliv solid
perform driven continu resili ms core
busi growth spinraza biosimilar spinraza continu
strong trajectori particularli outsid prepar
expect launch vumer believ import addit
market-lead multipl sclerosi portfolio made strong progress
pipelin initi new clinic program target parkinson diseas
brain contus look forward nine import data readout end
biopharmaceut compani base cambridg mass
special discov develop deliv innov therapi
peopl live seriou neurolog neurodegen diseas
compani state lead portfolio medicin treat multipl
sclerosi introduc first approv treatment spinal muscular atrophi
commerci biosimilar advanc biolog focus advanc
research program multipl sclerosi neuroimmunolog neuromuscular
disord movement disord alzheim diseas dementia ophthalmolog
immunolog neurocognit disord acut neurolog pain
eisai co ltd global research development-bas pharmaceut
compani headquart tokyo japan compani employ approxim
peopl global indic strateg focus area
neurolog oncolog firm market capit around
billion billion yen trade tokyo stock exchang
began day market capit billion
higher today compar yesterday close price
stock trade today
current trade
